Literature DB >> 31989838

Bactericidal efficacy of cold atmospheric plasma treatment against multidrug-resistant Pseudomonas aeruginosa.

Liyun Wang1, Chuankai Xia1, Yajun Guo1, Chunjun Yang1, Cheng Cheng2, Jun Zhao1, Xingyu Yang1, Zhicheng Cao1.   

Abstract

Aim: The global of spread multidrug-resistant Pseudomonas aeruginosa has become a public health threat. Cold atmospheric plasma (CAP) is reported to have bactericidal efficacy; however, its effects on clinical super multidrug-resistant P. aeruginosa are unclear. The aim of this study was to investigate the bactericidal efficacy of CAP on a strain of super multidrug-resistant P. aeruginosa. Materials & methods: The effects of CAP treatments were evaluated using assays for the detection of growth, viability, metabolism, virulence factors and reactive oxygen species (ROS) levels.
Results: Both CAP treatments dose-dependently inhibited cell viability and metabolic activity, and decreased the expression of several virulence factors. CAP treatment induced a significant increase in intracellular ROS levels, and ROS scavengers inhibited this effect.
Conclusion: CAP treatment is a promising option for the clinical inhibition of multidrug-resistant P. aeruginosa, and the development of CAP technologies might be the key to solving the long-standing problem of drug-resistant bacteria.

Entities:  

Keywords:  CAP; CAP treatments; CAP-activated liquid; cold atmospheric plasma; multidrug-resistant Pseudomonas aeruginosa; reactive oxygen species

Mesh:

Substances:

Year:  2020        PMID: 31989838     DOI: 10.2217/fmb-2019-0265

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  1 in total

1.  Non-thermal plasma causes Pseudomonas aeruginosa biofilm release to planktonic form and inhibits production of Las-B elastase, protease and pyocyanin.

Authors:  Petra Kašparová; Eva Vaňková; Martina Paldrychová; Alžběta Svobodová; Romana Hadravová; Irena Jarošová Kolouchová; Jan Masák; Vladimir Scholtz
Journal:  Front Cell Infect Microbiol       Date:  2022-09-23       Impact factor: 6.073

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.